Home/Sudo Biosciences/Imran Babar, PhD
IB

Imran Babar, PhD

Chief Business & Financial Officer

Sudo Biosciences

Therapeutic Areas

Sudo Biosciences Pipeline

DrugIndicationPhase
SUDO-550Neurological & Immunological Conditions (e.g., Multiple Sclerosis)Phase 1